At Julius Clinical, we are proud to announce the first formal meeting of our Dementia Scientific Advisory Board (SAB) with Prof. Philip Scheltens and Prof. John Harrison—a major milestone in our commitment to advancing dementia research and clinical trials.

About Julius Clinical

Founded in 2008 as a spin-off from the University Medical Center Utrecht, Julius Clinical stands out as a unique clinical research organization (CRO) specialising in Neurological disease. Our scientific focus and extensive investigator networks enables us to deliver innovative and flexible clinical trial solutions that address critical unmet medical needs.

Our expertise in the field of Dementia clinical research not only spans industry-sponsored  clinical trial research, but also investigator-initiated trials and observational studies. While our long-term aim is to become a leading CRO for all dementia indications, our current focus is on growing our dementia trials portfolio and staying at the forefront of developments in this rapidly evolving field.

The Role and Vision of the Dementia SAB

The Dementia SAB is a vital step in strengthening our presence in dementia clinical research. Its mission is to support the growth of our dementia portfolio by:

  • Providing Strategic Guidance: Advising on novel scientific developments and identifying key opportunities in dementia drug development.
  • Fostering Collaboration: Enhancing our engagement with global experts and building a stronger network to advance clinical trial excellence.

The Dementia SAB will convene bi-annually for a dedicated meeting chaired by our Scientific Officer for Neurology, Dr. Lieza Exalto. These meetings will serve as a platform to:

  1. Share updates on Julius Clinical’s progress, ongoing activities, and future goals.
  2. Gain insights from SAB members on pivotal advancements in dementia drug development.
  3. Receive strategic guidance on expanding and optimizing our dementia research capabilities.

In addition to the annual meeting, SAB members will also be consulted on an ad hoc basis to:

  • Provide expert opinions and scientific input to assist in addressing queries from partners and clients.
  • Contribute to key initiatives, such as clinical trial networks, research grants, and presentations at conferences or webinars.

Looking Ahead

The establishment of the Dementia SAB reflects Julius Clinical’s dedication to staying at the forefront of dementia research. By leveraging the expertise of leading scientists and clinicians, we aim to make meaningful strides in developing and executing clinical trials that address the urgent needs of patients and healthcare providers.

As we continue to grow and innovate, we remain committed to our academic roots while embracing the flexibility and focus required to be a leader in dementia clinical research.

For more information about our work or opportunities to collaborate, contact us.